UpdatesPress Release
SRF Q3FY26 PAT soared 60% to ₹433 Cr, driven by robust Chemicals Business growth (revenue +22%). Fluorochemicals achieved record performance.
SRF LimitedSRF · Filed with the exchange
The board approved a ₹5/share interim dividend and a ₹180 Cr capex for a new Pharma Intermediates plant.
No comments yet. Be the first.